Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Releases New High-CBD, Low-THC Gummies Designed to Address Pain, Stress and Anxiety

  • Plus Products releases PLUS CBDRelief brand into the California adult-use market
  • New product line currently includes two products: PLUS CBDRelief 9:1 Tropical Mango and PLUS CBDRelief 18:1
  • PLUS CBDRelief products specifically formulated to help reduce chronic subclinical inflammation, provide full-body relief and promote a calm state of mind

With its gummy products consistently ranking tops in California, the world’s largest cannabis market, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) is focusing its current efforts on maintaining its best-selling spot as well as expanding market share in a category that has historically remained underserved. PLUS plans to accomplish both with the launch of its newest line of products – two high-CBD, low-THC gummies designed to fill a hole in the wellness and relief-market cannabis category.

This month Plus Products released its PLUS CBDRelief brand into the California adult-use market ( The product line currently includes two products: PLUS CBDRelief 9:1 Tropical Mango with 9 mg of CBD and 1 mg of THC per serving and PLUS CBDRelief 18:1 Tart Cherry with 18 mg of CBD and 1 mg of THC per serving. The PLUS CBDRelief cannabis-infused gummies are expected to be available statewide in coming weeks.

“We have seen compelling success with our core brand and are excited to take the next step towards becoming a true portfolio of brands with the launch of PLUS CBDRelief,” PLUS co-founder and CEO Jake Heimark stated in a news release. “Last year we partnered with market structure research firm HJR Associates and found that when consumers used cannabis, over one-third of the time it was to address pain, stress or anxiety. This represents a massive market that appears, thus far, to have been underserved. We believe there are almost no edibles products in California designed to meet the needs of these consumers, and we’re excited to introduce products formulated specifically for that purpose.”

PLUS CBDRelief products are specifically formulated to help reduce chronic subclinical inflammation, provide full-body relief and promote a calm state of mind. The proprietary products contain an exclusive mix of high-quality CBD and THC to deliver the highest cannabinoid content per package among gummies in the California marketplace; the products are also deliberately designed in dosages that enable consumers to precision dose, or control the dosages they receive based on individual response and desires.

The new PLUS CBDRelief brand is a strong addition to Plus Products core brand, which was the largest cannabis-infused gummies brand in California in 2019 and ranked as the best-selling cannabis product in the state across all categories over the same period.

“Research suggests that people are looking to cannabis as a holistic tool for relief,” PLUS Chief Scientific Officer Ari Mackler stated in a news release. “It’s exciting to leverage rigorous science to formulate great products that enable people to help themselves. Research on cannabis is progressing quickly, and we are driving our portfolio of products with innovative science and technologies that will support our customers’ health and wellness goals.”

Plus Products is well positioned for greater growth in California. The company has also taken its top-selling product into Nevada. Of note for investors is that PLUS has a strong management team and a clean capital structure with considerable insider ownership. The company continues to build the world’s largest cannabis brand by applying its successful formula to new products and consumers.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.


Select A Month

CBDWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 303.498.7722